Macular Neovascularization Explained From Causes to Cutting-Edge Treatments
A comprehensive review covers MNV origins, multimodal imaging diagnosis, and anti-VEGF therapies for macular diseases threatening central vision.
Summary
Macular neovascularization (MNV) is an abnormal blood vessel growth in the macula triggered by ischemia and inflammation, commonly seen in age-related macular degeneration, polypoidal choroidal vasculopathy, and pathologic myopia. Driven by excess VEGF from retinal pigment epithelium and Müller cells, MNV causes metamorphopsia, central vision loss, and color recognition problems. The CONAN study group standardized the term 'MNV' to encompass intraretinal, subretinal, and sub-pigment epithelial neovascularization. Diagnosis relies on multimodal imaging including OCT, OCT angiography, and dye-based angiography. Standard treatment involves intravitreal anti-VEGF injections, with laser photocoagulation, photodynamic therapy, and vitreoretinal surgery reserved for select cases.
Detailed Summary
Central vision is among the most critical faculties for independent living, and macular neovascularization (MNV) represents one of its most serious threats. As populations age globally, conditions like neovascular age-related macular degeneration (nAMD) are becoming increasingly prevalent, making a thorough understanding of MNV essential for clinicians and informed patients alike.
This comprehensive review from an international team of vitreoretinal specialists synthesizes current knowledge on MNV — its pathophysiology, classification, diagnosis, and treatment. MNV arises when localized ischemia and inflammation drive excessive VEGF production by the retinal pigment epithelium and Müller cells, stimulating abnormal vessel growth from either the choriocapillaris or retinal microvasculature into or beneath the macula.
The CONAN study group proposed unifying terminology — 'macular neovascularization' — to encompass previously fragmented nomenclature covering intraretinal, subretinal, and sub-pigment epithelial lesions. Clinically, MNV presents as a grey-green macular lesion with overlying retinal thickening or exudation, causing metamorphopsia, central scotoma, reduced reading speed, and impaired color vision. Multimodal imaging tools including OCT, OCT angiography, fundus autofluorescence, and dye-based angiography are indispensable for accurate diagnosis and treatment planning.
The mainstay of treatment remains intravitreal anti-VEGF injections, which have revolutionized outcomes for nAMD and related conditions. Thermal laser photocoagulation, verteporfin photodynamic therapy, and vitreoretinal surgery serve as adjuncts in specific clinical scenarios.
As a review article based solely on the abstract, granular data on treatment outcomes are not available here. However, the standardization of MNV nomenclature and emphasis on multimodal imaging mark meaningful progress toward consistent diagnosis and management across clinical settings worldwide.
Key Findings
- MNV results from VEGF overproduction by RPE and Müller cells driven by ischemia and inflammation.
- CONAN group unified MNV terminology to include intraretinal, subretinal, and sub-RPE neovascularization.
- Symptoms include metamorphopsia, central scotoma, reduced reading speed, and impaired color recognition.
- Multimodal imaging — OCT, OCTA, dye angiography — is essential for diagnosis and treatment selection.
- Anti-VEGF intravitreal injections are the standard of care; laser and PDT are used selectively.
Methodology
This is a comprehensive narrative review published in Survey of Ophthalmology by an international panel of vitreoretinal specialists. It synthesizes existing literature on MNV pathophysiology, imaging, and therapeutics. No primary clinical trial data or meta-analysis methodology is described in the abstract.
Study Limitations
As a review article, this summary reflects synthesized expert opinion rather than novel primary data, limiting direct evidence grading. Only the abstract was available for analysis, so specific data on treatment outcomes, patient populations, or evidence hierarchies could not be assessed. Some authors disclosed consulting relationships with pharmaceutical companies, which may introduce potential bias in treatment recommendations.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.
Enter your email to subscribe: